+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Rheumatoid Arthritis Therapeutics Market Size, Share & Trends Analysis Report by Molecule (Pharmaceuticals, Biopharmaceuticals), by Sales Channel (Prescription, Over-the-Counter), by Region, and Segment Forecasts, 2025-2033- Product Image
Rheumatoid Arthritis Therapeutics Market Size, Share & Trends Analysis Report by Molecule (Pharmaceuticals, Biopharmaceuticals), by Sales Channel (Prescription, Over-the-Counter), by Region, and Segment Forecasts, 2025-2033- Product Image
New

Rheumatoid Arthritis Therapeutics Market Size, Share & Trends Analysis Report by Molecule (Pharmaceuticals, Biopharmaceuticals), by Sales Channel (Prescription, Over-the-Counter), by Region, and Segment Forecasts, 2025-2033

  • PDF Icon

    Report

  • 150 Pages
  • August 2025
  • Region: Global
  • Grand View Research
  • ID: 5990619
Description Jump to:
The global rheumatoid arthritis therapeutics market size was estimated at USD 25.76 billion in 2024 and is projected to reach USD 41.42 billion by 2033, growing at a CAGR of 5.56% from 2025 to 2033. The introduction of innovative therapeutics for rheumatoid arthritis (RA) is playing a key role in boosting market growth.

The launch of new biosimilars such as Cyltezo, Hyrimoz, Amgevita, Erelzi, Avsola, and Rituximab by leading pharmaceutical companies including Amgen Inc., Pfizer Inc., Genentech, Inc., and Novartis has significantly reshaped the RA treatment landscape. For instance, In May 2024, Boehringer Ingelheim announced that the U.S. Food and Drug Administration had approved a high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm) the company’s interchangeable biosimilar to Humira for treating multiple chronic inflammatory diseases including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis, psoriatic arthritis, hidradenitis suppurativa, ankylosing spondylitis, moderate-to-severe plaque psoriasis, and non-infectious uveitis.

In a similar development, January 2023 saw Novartis AG secure marketing authorization from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Sandoz’s citrate-free, high-concentration formulation (HCF) of Hyrimoz (adalimumab). This approval extends to all indications of the reference medicine, including RA, uveitis, ulcerative colitis, and plaque psoriasis. These next-generation biologics and biosimilars are designed to act on specific immune system molecules or receptors responsible for joint pain and inflammation, resulting in improved treatment outcomes. Rising demand for such targeted and efficient therapies is expected to further drive advancements in biologic treatments for RA.

In recent years, RA treatment strategies have shifted toward newer molecules capable of inducing disease remission. This evolution stems from a deeper understanding of RA’s underlying mechanisms, leading to the creation of targeted biologic and synthetic disease-modifying antirheumatic drugs (DMARDs). While first-line treatment still includes small-molecule DMARDs, corticosteroids, analgesics, and nonsteroidal anti-inflammatory drugs (NSAIDs), these options primarily slow disease progression and manage inflammation rather than curing the condition. Moreover, they can cause notable side effects, such as gastrointestinal ulcers, immunosuppression, osteoporosis, nausea, cytopenia, fatigue, skin rashes, liver damage, psoriasis, and an increased risk of infections.

Global Rheumatoid Arthritis Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. The analyst has segmented the global rheumatoid arthritis therapeutics market report based on molecule, sales channel, and region:

Molecule Outlook (Revenue, USD Million, 2021-2033)

  • Pharmaceuticals
  • NSAIDs
  • Analgesics
  • DMARDs
  • Glucocorticoids
  • Biopharmaceuticals
  • Biologics
  • TNF-α antagonists
  • T-cell inhibitors
  • CD20 antigen
  • JAK inhibitors
  • Anti-IL6 biologics
  • Biosimilars
  • CD20 antigen
  • TNF-α antagonists

Sales Channel Outlook (Revenue, USD Million, 2021-2033)

  • Prescription
  • Over-the-Counter (OTC)

Regional Outlook (Revenue, USD Million, 2021-2033)

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Latin America
  • Brazil
  • Argentina
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the industry across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segmental and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Molecule
1.2.2. Sales Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Rheumatoid Arthritis Therapeutics Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Rheumatoid Arthritis Therapeutics Market: Molecule Business Analysis
4.1. Molecule Market Share, 2024 & 2033
4.2. Molecule Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Molecule, 2021 to 2033 (USD Million)
4.4. Pharmaceuticals
4.4.1. Pharmaceuticals Market, 2021-2033 (USD Million)
4.4.2. NSAIDs
4.4.2.1. NSAIDs Market, 2021-2033 (USD Million)
4.4.3. Analgesics
4.4.3.1. Analgesics Market, 2021-2033 (USD Million)
4.4.4. DMARDs
4.4.4.1. DMARDs Market, 2021-2033 (USD Million)
4.4.5. Glucocorticoids
4.4.5.1. Glucocorticoids Market, 2021-2033 (USD Million)
4.5. Biopharmaceuticals
4.5.1. Biopharmaceuticals Market, 2021-2033 (USD Million)
4.5.2. Biologics
4.5.2.1. Biologics Market, 2021-2033 (USD Million)
4.5.2.2. TNF-a antagonists
4.5.2.2.1. TNF-a antagonists Market, 2021-2033 (USD Million)
4.5.2.3. T-cell inhibitors
4.5.2.3.1. T-cell inhibitors Market, 2021-2033 (USD Million)
4.5.2.4. CD20 antigen
4.5.2.4.1. CD20 antigen Market, 2021-2033 (USD Million)
4.5.2.5. JAK inhibitors
4.5.2.5.1. JAK inhibitors Market, 2021-2033 (USD Million)
4.5.2.6. Anti-IL6 biologics
4.5.2.6.1. Anti-IL6 biologics Market, 2021-2033 (USD Million)
4.5.3. Biosimilars
4.5.3.1. Biosimilars Market, 2021-2033 (USD Million)
4.5.3.2. CD20 antigen
4.5.3.2.1. CD20 antigen Market, 2021-2033 (USD Million)
4.5.3.3. TNF-a antagonists
4.5.3.3.1. TNF-a antagonists Market, 2021-2033 (USD Million)
Chapter 5. Rheumatoid Arthritis Therapeutics Market: Sales Channel Business Analysis
5.1. Sales Channel Market Share, 2024 & 2033
5.2. Sales Channel Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2021 to 2033 (USD Million)
5.4. Prescription
5.4.1. Prescription Market, 2021-2033 (USD Million)
5.5. Over-the-Counter (OTC)
5.5.1. Over-the-Counter (OTC) Market, 2021-2033 (USD Million)
Chapter 6. Rheumatoid Arthritis Therapeutics Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2033
6.2. Regional Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
6.4. North America
6.4.1. North America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, by Country, 2021-2033 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Regulatory Framework
6.4.2.4. Reimbursement Framework
6.4.2.5. U.S. Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Regulatory Framework
6.4.3.4. Reimbursement Framework
6.4.3.5. Canada Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Regulatory Framework
6.4.4.4. Reimbursement Framework
6.4.4.5. Mexico Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5. Europe
6.5.1. Europe Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamics
6.5.2.2. Target Disease Prevalence
6.5.2.3. Regulatory Framework
6.5.2.4. Reimbursement Framework
6.5.2.5. UK Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Regulatory Framework
6.5.3.4. Reimbursement Framework
6.5.3.5. Germany Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Regulatory Framework
6.5.4.4. Reimbursement Framework
6.5.4.5. France Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Target Disease Prevalence
6.5.5.3. Regulatory Framework
6.5.5.4. Reimbursement Framework
6.5.5.5. Italy Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamics
6.5.6.2. Target Disease Prevalence
6.5.6.3. Regulatory Framework
6.5.6.4. Reimbursement Framework
6.5.6.5. Spain Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5.7. Denmark
6.5.7.1. Key Country Dynamics
6.5.7.2. Target Disease Prevalence
6.5.7.3. Regulatory Framework
6.5.7.4. Reimbursement Framework
6.5.7.5. Denmark Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5.8. Sweden
6.5.8.1. Key Country Dynamics
6.5.8.2. Target Disease Prevalence
6.5.8.3. Regulatory Framework
6.5.8.4. Reimbursement Framework
6.5.8.5. Sweden Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5.9. Norway
6.5.9.1. Key Country Dynamics
6.5.9.2. Target Disease Prevalence
6.5.9.3. Regulatory Framework
6.5.9.4. Reimbursement Framework
6.5.9.5. Norway Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.6. Asia-Pacific
6.6.1. Asia-Pacific Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamics
6.6.2.2. Target Disease Prevalence
6.6.2.3. Regulatory Framework
6.6.2.4. Reimbursement Framework
6.6.2.5. Japan Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Regulatory Framework
6.6.3.4. Reimbursement Framework
6.6.3.5. China Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Regulatory Framework
6.6.4.4. Reimbursement Framework
6.6.4.5. India Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.6.5. Australia
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Regulatory Framework
6.6.5.4. Reimbursement Framework
6.6.5.5. Australia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.6.6. South Korea
6.6.6.1. Key Country Dynamics
6.6.6.2. Target Disease Prevalence
6.6.6.3. Regulatory Framework
6.6.6.4. Reimbursement Framework
6.6.6.5. South Korea Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.6.7. Thailand
6.6.7.1. Key Country Dynamics
6.6.7.2. Target Disease Prevalence
6.6.7.3. Regulatory Framework
6.6.7.4. Reimbursement Framework
6.6.7.5. Thailand Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.7. Latin America
6.7.1. Latin America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Target Disease Prevalence
6.7.2.3. Regulatory Framework
6.7.2.4. Reimbursement Framework
6.7.2.5. Brazil Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Target Disease Prevalence
6.7.3.3. Regulatory Framework
6.7.3.4. Reimbursement Framework
6.7.3.5. Argentina Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.8. Middle East and Africa
6.8.1. Middle East and Africa Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Target Disease Prevalence
6.8.2.3. Regulatory Framework
6.8.2.4. Reimbursement Framework
6.8.2.5. South Africa Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Target Disease Prevalence
6.8.3.3. Regulatory Framework
6.8.3.4. Reimbursement Framework
6.8.3.5. Saudi Arabia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Target Disease Prevalence
6.8.4.3. Regulatory Framework
6.8.4.4. Reimbursement Framework
6.8.4.5. UAE Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Target Disease Prevalence
6.8.5.3. Regulatory Framework
6.8.5.4. Reimbursement Framework
6.8.5.5. Kuwait Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. AbbVie, Inc.
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Molecule Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Boehringer Ingelheim International GmbH
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Molecule Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Novartis AG
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Molecule Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. Regeneron Pharmaceuticals Inc.
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Molecule Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Pfizer, Inc.
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Molecule Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. Bristol-Myers Squibb Company
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Molecule Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. F. Hoffmann-La Roche Ltd.
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.3. Molecule Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. UCB S.a.
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Molecule Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Johnson & Johnson Services, Inc.
7.5.9.1. Overview
7.5.9.2. Financial Performance
7.5.9.3. Molecule Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. Amgen, Inc.
7.5.10.1. Overview
7.5.10.2. Financial Performance
7.5.10.3. Molecule Benchmarking
7.5.10.4. Strategic Initiatives
7.5.11. Lilly (Eli Lilly and Company)
7.5.11.1. Overview
7.5.11.2. Financial Performance
7.5.11.3. Molecule Benchmarking
7.5.11.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 4 Global rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 5 North America rheumatoid arthritis therapeutics market, by region, 2021-2033 (USD Million)
Table 6 North America rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 7 North America rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 8 U.S. rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 9 U.S. rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 10 Canada rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 11 Canada rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 12 Mexico rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 13 Mexico rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 14 Europe rheumatoid arthritis therapeutics market, by country, 2021-2033 (USD Million)
Table 15 Europe rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 16 Europe rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 17 UK rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 18 UK rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 19 Germany rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 20 Germany rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 21 France rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 22 France rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 23 Italy rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 24 Italy rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 25 Spain rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 26 Spain rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 27 Norway rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 28 Norway rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 29 Sweden rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 30 Sweden rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 31 Denmark rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 32 Denmark rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 33 Asia-Pacific rheumatoid arthritis therapeutics market, by country, 2021-2033 (USD Million)
Table 34 Asia-Pacific rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 35 Asia-Pacific rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 36 Japan rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 37 Japan rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 38 China rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 39 China rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 40 India rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 41 India rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 42 Australia rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 43 Australia rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 44 South Korea rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 45 South Korea rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 46 Thailand rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 47 Thailand rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 48 Latin America rheumatoid arthritis therapeutics market, by country, 2021-2033 (USD Million)
Table 49 Latin America rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 50 Latin America rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 51 Brazil rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 52 Brazil rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 53 Argentina rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 54 Argentina rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 55 Middle East & Africa rheumatoid arthritis therapeutics market, by country, 2021-2033 (USD Million)
Table 56 Middle East & Africa rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 57 Middle East & Africa rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 58 South Africa rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 59 South Africa rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 60 Saudi Arabia rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 61 Saudi Arabia rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 62 UAE rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 63 UAE rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
Table 64 Kuwait rheumatoid arthritis therapeutics market, by molecule, 2021-2033 (USD Million)
Table 65 Kuwait rheumatoid arthritis therapeutics market, by sales channel, 2021-2033 (USD Million)
List of Figures
Figure 1 Rheumatoid arthritis therapeutics market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Therapeutic approach and molecule outlook (USD Million)
Figure 10 Competitive landscape
Figure 11 Rheumatoid arthritis therapeutics market dynamics
Figure 12 Rheumatoid arthritis therapeutics market: Porter’s five forces analysis
Figure 13 Rheumatoid arthritis therapeutics market: PESTLE analysis
Figure 14 Molecule market estimates and forecast, 2021-2033 (USD Million)
Figure 15 Biopharmaceuticals market estimates and forecast, 2021-2033 (USD Million)
Figure 16 Biologics market estimates and forecast, 2021-2033 (USD Million)
Figure 17 TNF-a antagonists market estimates and forecast, 2021-2033 (USD Million)
Figure 18 T-cell inhibitors market estimates and forecast, 2021-2033 (USD Million)
Figure 19 CD20 antigen market estimates and forecast, 2021-2033 (USD Million)
Figure 20 JAK inhibitors market estimates and forecast, 2021-2033 (USD Million)
Figure 21 Anti-IL6 biologics market estimates and forecast, 2021-2033 (USD Million)
Figure 22 Biosimilars market estimates and forecast, 2021-2033 (USD Million)
Figure 23 CD20 antigen market estimates and forecast, 2021-2033 (USD Million)
Figure 24 TNF-a antagonists market estimates and forecast, 2021-2033 (USD Million)
Figure 25 Pharmaceuticals market estimates and forecast, 2021-2033 (USD Million)
Figure 26 NSAIDs market estimates and forecast, 2021-2033 (USD Million)
Figure 27 Analgesics market estimates and forecast, 2021-2033 (USD Million)
Figure 28 DMARDs market estimates and forecast, 2021-2033 (USD Million)
Figure 29 Glucocorticoids market estimates and forecast, 2021-2033 (USD Million)
Figure 30 Rheumatoid arthritis therapeutics: Sales channel outlook and key takeaways
Figure 31 Rheumatoid arthritis therapeutics market: Sales channel market movement analysis
Figure 32 Prescription market estimates and forecast, 2021-2033 (USD Million)
Figure 33 Over-the-Counter (OTC) market estimates and forecast, 2021-2033 (USD Million)
Figure 34 Rheumatoid arthritis therapeutics market revenue, by region
Figure 35 Regional marketplace: Key takeaways
Figure 36 North America rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 37 US country dynamics
Figure 38 US rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 39 Canada country dynamics
Figure 40 Canada rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 41 Mexico country dynamics
Figure 42 Mexico rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 43 Europe rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 44 UK country dynamics
Figure 45 UK rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 46 Germany country dynamics
Figure 47 Germany rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 48 France country dynamics
Figure 49 France rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 50 Italy country dynamics
Figure 51 Italy rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 52 Spain country dynamics
Figure 53 Spain rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 54 Norway country dynamics
Figure 55 Norway rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 56 Sweden country dynamics
Figure 57 Sweden rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 58 Denmark country dynamics
Figure 59 Denmark rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 60 Asia-Pacific rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 61 Japan country dynamics
Figure 62 Japan rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 63 China country dynamics
Figure 64 China rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 65 India country dynamics
Figure 66 India rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 67 Australia country dynamics
Figure 68 Australia rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 69 South Korea country dynamics
Figure 70 South Korea rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 71 Thailand country dynamics
Figure 72 Thailand rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 73 Latin America rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 74 Brazil country dynamics
Figure 75 Brazil rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 76 Argentina country dynamics
Figure 77 Argentina rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 78 MEA rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 79 South Africa country dynamics
Figure 80 South Africa rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 81 Saudi Arabia country dynamics
Figure 82 Saudi Arabia rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 83 UAE country dynamics
Figure 84 UAE rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 85 Kuwait country dynamics
Figure 86 Kuwait rheumatoid arthritis therapeutics market, 2021-2033 (USD Million)
Figure 87 Company categorization
Figure 88 Company market position analysis
Figure 89 Strategic framework

Companies Mentioned

The major companies profiled in this Rheumatoid Arthritis Therapeutics market report include:
  • AbbVie, Inc.
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.
  • Pfizer, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • UCB S.A.
  • Johnson & Johnson Services, Inc.
  • Amgen, Inc.
  • Lilly (Eli Lilly and Company)

Table Information

Report AttributeDetails
No. of Pages150
PublishedAugust 2025
Forecast Period2024 - 2033
Estimated Market Value ( USD ) in 2024 $ 25.76 Billion
Forecasted Market Value ( USD ) by 2033 $ 41.42 Billion
Compound Annual Growth Rate5.5%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Autoimmune Disease Diagnosis Market Size, Share, Trends and Forecast by Product Type, Disease Type, Test Type, End-User, and Region, 2025-2033 - Product Image

Autoimmune Disease Diagnosis Market Size, Share, Trends and Forecast by Product Type, Disease Type, Test Type, End-User, and Region, 2025-2033

  • Report
  • 149 Pages
  • Global
From
Rheumatoid Arthritis Therapeutics - Global Strategic Business Report - Product Image

Rheumatoid Arthritis Therapeutics - Global Strategic Business Report

  • Report
  • 150 Pages
  • Global
From
InterLeukin6 IL6 Inhibitor Market 2024 - Product Image

InterLeukin6 IL6 Inhibitor Market 2024

  • Report
  • 175 Pages
  • Global
From
Auranofin Market - Global Forecast 2025-2030 - Product Image

Auranofin Market - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Interleukin Inhibitors for Rheumatoid Arthritis Market - Global Forecast 2025-2030 - Product Image

Interleukin Inhibitors for Rheumatoid Arthritis Market - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.